

AMICUS AND OTSUKA SIGN DISTRIBUTION DEAL FOR JINARC[®] ▼ (TOLVAPTAN)

AMICUS ANNOUNCEMENT NO. 22

March 11th, 2019

Amicus SA and Otsuka Pharmaceutical Europe Ltd. signed an exclusive distribution agreement today under which Amicus will commercialise and support patient access to Otsuka's product JINARC[®] (tolvaptan) across all of Central and Eastern European EU countries as well as two Western European countries.

Baar, Switzerland, March 11th, 2019: Amicus S.A. of Baar, Switzerland announced today that a distribution agreement with Otsuka Pharmaceutical Europe Ltd. of Wexham, United Kingdom, has been signed. The agreement, which is effective immediately, provides for Amicus to render promotion, distribution, regulatory, medical, pharmacovigilance, warehousing and related services for Otsuka's product JINARC[®] (tolvaptan) in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia.

"This contract sets yet another precedent for Amicus", commented Amicus CEO Jean-Michel Lespinasse. "Otsuka is a global pharmaceutical player, and to be chosen to represent Otsuka's product tolvaptan, and thereby to bring much-needed access to an approved treatment for patients suffering from autosomal dominant polycystic kidney disease (ADPKD) across all of Central & Eastern Europe and Greece / Cyprus, is a genuine privilege. Not only does this contract expand our geographical coverage into new territories for Amicus, it also deepens Amicus' presence in nephrology. JINARC[®] is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease¹. Work has now begun to seek approval for a required Risk Management Plan and agreement for Pricing and Re-imburement from the relevant competent authorities, initially in Czech Republic and Hungary, prior to patients having access to tolvaptan. We are delighted to have been granted this opportunity to work with Tolvaptan and Otsuka."

About Amicus S.A.

Established in 2014, Amicus has gathered outstanding pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands. Amicus now operates fully-owned subsidiaries across all of Central and Eastern Europe, with the exception of Russia and the CIS countries. Sales in 2018 exceeded 70 million Euros and in 2019 should top 100 million Euros.

For more info about Amicus, please visit:

www.Amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321

Reference

¹Jinarc SMPC February 2019

Job code: OPUK/0319/COMS/1034

Date of preparation: March 8th, 2019